Current research targeting the VEGF pathway is focused on ligand inhibitors, receptor inhibitors, VEGF decoy receptors, and ribozymes targeting VEGF, of which select inhibitors are marketed to treat CRC, RCC, HCC, solid tumors, and gastrointestinal tumors. Here, VEGFA is linked to renal cell carcinoma.